- Chugai Pharma Manufacturing's FJ3 began construction in March 2022 and was completed in November 2024 to support late‑stage development and early commercial API production.
- FJ3 enables dual manufacturing of macrocyclic‑peptide APIs (from the SnipeTide platform) and conventional small‑molecule APIs within shared facilities.
- Containment technologies control airborne concentrations to 0.03 µg/m3 or less, supporting large‑scale handling of highly potent APIs.
- Facility uses advanced automation, digitalization and parallel multi‑line operation to reduce operator workload and maintain productivity.
Award recognition
FJ3 at the Fujieda Plant received the ISPE Facility of the Year Awards (FOYA) 2026 Honorable Mention for its facility design and manufacturing capabilities; this follows FJ2’s 2023 Innovation award and Ukima UK4’s 2024 Social Impact award.
Facility scope and timeline
FJ3 is an API manufacturing building for late‑stage development and early commercial production of small molecules and macrocyclic peptide drugs; construction began in March 2022 and was completed in November 2024.
Technical capabilities
The building supports Dual Manufacturing Capability to run macrocyclic‑peptide and conventional small‑molecule API processes in shared facilities, uses advanced automation and digitalization with parallel multi‑line operation to reduce operator workload, and implements containment technologies controlling airborne concentration to 0.03 µg/m3 or less; the design also includes measures to minimize environmental impact in an explosion and a base‑isolated structure.
Macrocyclic peptide manufacturing and supply role
Macrocyclic peptides from the SnipeTide platform are complex cyclic peptides containing many non‑natural amino acids, requiring more steps and stricter purification and containment than small molecules; FJ3, together with FJ1 and FJ2, forms an integrated in‑house supply system covering early clinical development through early commercial production.
